Skip to main content
Debjani Pal’s photo “Three-Dimensional Breast Cancer Spheroids” won the Director’s Choice Award in Oak Ridge National Laboratory’s Art of Science photo competition. It will be displayed at the American Museum of Science and Energy in Oak Ridge, Tenn. Credit: Debjani Pal/ORNL, U.S. Dept. of Energy
“Three-Dimensional Breast Cancer Spheroids” submitted by radiotherapeutics researcher Debjani Pal is stunning. Brilliant blue dots pop from an electric sphere threaded with bright colors: greens, aqua, hot pink and red.
Seeing the difference Ac-225 could make to cancer patients made Raina Setzer want to come to ORNL to directly work with the isotope. Credit: Allison Peacock/ORNL, U.S. Dept. of Energy

Raina Setzer knows the work she does matters. That’s because she’s already seen it from the other side. Setzer, a radiochemical processing technician in Oak Ridge National Laboratory’s Isotope Processing and Manufacturing Division, joined the lab in June 2023.

The sun sets behind the ORNL Visitor Center in this aerial photo from April 2023. Credit: Kase Clapp/ORNL, U.S. Dept. of Energy

In fiscal year 2023 — Oct. 1–Sept. 30, 2023 — Oak Ridge National Laboratory was awarded more than $8 million in technology maturation funding through the Department of Energy’s Technology Commercialization Fund, or TCF.

UKAEA will provide novel fusion materials to be irradiated in ORNL’s HFIR facility over the next four years. From left, Kathy McCarthy, Jeremy Busby, Mickey Wade, Prof Sir Ian Chapman (UKAEA CEO), Cynthia Jenks and Yutai Kato will represent this new partnership. Not pictured: Dr. Amanda Quadling, UKAEA’s Director of Materials Research Facility. Credit: Genevieve Martin/ORNL, U.S. Dept. of Energy

ORNL has entered a strategic research partnership with the United Kingdom Atomic Energy Authority, or UKAEA, to investigate how different types of materials behave under the influence of high-energy neutron sources. The $4 million project is part of UKAEA's roadmap program, which aims to produce electricity from fusion.

Sandra Davern performs cell based assays to evaluate cell death and DNA damage in response to radiation in order to gain a better understanding of how radioisotope nanoparticles affect the human body.

When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.